Adding Cladribine to Standard Induction Regimen Improves AML Survival

Share this content:

(ChemotherapyAdvisor) – Adding the purine analog cladribine — but not fludarabine — to daunorubicin and cytarabine during induction has been found to increase complete remission rates and improve survival in adult patients with acute myeloid leukemia (AML), according to a study in the Journal of Clinical Oncology online April 16.

The investigators noted that these results suggest the daunorubicin/cytarabine/cladribine regimen be considered the new standard of care as remission induction.

The multicenter Phase 3 trial in Poland randomized 652 treatment-naïve patients with AML to one of three induction regimens: daunorubicin/cytarabine, daunorubicin/cytarabine/cladribine, or daunorubicin/cytarabine/fludarabine. Postremission treatment was the same for all arms. Median age of was 47 years (range, 17 to 60).

Patients in the cladribine arm had a higher complete remission rate vs. daunorubicin/cytarabine alone (67.5% vs. 56%; P=0.01) as a consequence of reduced incidence of resistant disease (21% vs. 34%; P=0.004). No significant difference in early outcome between the daunorubicin/cytarabine and the fludarabine arms was observed.

Probability of overall survival was improved for the daunorubicin/cytarabine/cladribine arm (45% ± 4% at three years) vs. the daunorubicin/cytarabine arm (33% ± 4%; P=0.02); leukemia-free survival was comparable. Long-term outcome did not differ significantly when the daunorubicin/cytarabine and daunorubicin/cytarabine/fludarabine arms were compared.

Compared with the daunorubicin/cytarabine arm, a survival advantage of the addition of cladribine was observed among patients age 50 years or older (P=0.005), those with initial leukocyte count above 50×109/L (P=0.03), and those with unfavorable karyotype (P=0.03), the investigators found. In patients with adverse karyotype, the addition of fludarabine revealed a significant advantage over daunorubicin/cytarabine (P=0.02).

Hematologic and nonhematologic toxicities were comparable among treatment arms, indicating that the addition of purine analogs did not impair treatment tolerance.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs